Dicot Pharma AB OMXSTO:DICOT:
SIGNS AGREEMENT WITH CRO AHEAD OF PHASE 2B STUDY WITH LIB-01
STUDY WILL BE CONDUCTED IN US AND EUROPE AND IS EXPECTED TO START DURING SECOND HALF OF 2026.
Dicot Pharma Signs Agreement With CRO Ahead Of Phase 2B Study With Lib-01
Earlier from Dicot Pharma
- Dicot Pharma Submits Patent Application For LIB-01
- Dicot Pharma Q3 Loss After Financial Items SEK 16.1 Mln
- DICOT: Phase 2a study enrollment completed; strong cash position supports next development steps
- DICOT: Strong warrant uptake and robust cash position support ongoing LIB-01 clinical progress
- Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million
Later from Dicot Pharma
- Dicot Pharma to present at the Oppenheimer 36th Healthcare Life Sciences Conference
- DICOT: LIB-01 demonstrated long-lasting efficacy in phase 2a, supporting further clinical development
- Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study
- Notice of annual general meeting in DICOT Pharma AB
- Pharma publishes its Annual Report for 2025
Follow Dicot Pharma into a list and get an email when it puts out news.
Follow Dicot Pharma